Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MPO | P05164 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 1/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8699883 | 1.00 | KDM4E (0.69) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL7593998 | 0.95 | KDM4E (0.63) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL30052868 | 0.91 | KDM4E (0.60) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL29378473 | 0.90 | KDM4E (0.65) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL18541537 | 0.90 | KDM4E (0.65) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL16317501 | 0.90 | KDM4E (0.65) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL9868659 | 0.90 | OPRM1 (0.66) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL29391520 | 0.90 | OPRM1 (0.66) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL31016727 | 0.89 | KDM4E (0.58) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL20375720 | 0.89 | KDM4E (0.64) | KDM4EMAPTMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4511052-A2 | EPHRIN LIGAND MIMETIC PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | University of Miami (US) | 2025-02-26 | — | — | EP | claimed |
| US-20250042968-A1 | EPHRIN LIGAND MIMETIC PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV MIAMI (US) | 2025-02-06 | — | — | US | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| CN-117003829-A | Oil control polypeptide compound, preparation method and application thereof | 成都凯捷多肽科技有限公司 | 2023-11-07 | — | — | CN | claimed |
| WO-2023205752-A2 | EPHRIN LIGAND MIMETIC PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF MIAMI (US) | 2023-10-26 | — | — | WO | claimed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | claimed |
| EP-4017281-A1 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| EP-3947743-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-02-09 | — | — | EP | claimed |
| WO-2021127701-A1 | PET FOOD COMPOSITIONS | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0381997-A1 | Microbially prepared N-acetyl-2,3-didehydroleucine acylase, process for its preparation and its use | Degussa Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | claimed |
| JP-2023849-A | — | — | None | — | — | JP | disclosed |
| JP-2004715-A | — | — | None | — | — | JP | disclosed |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | ACTICOR BIOTECH (FR) | 2026-05-19 | — | — | US | disclosed |
| EP-0234186-A1 | Use of oligopeptids for the treatment of cerebral disorders | Fresenius AG (DE) | 1987-09-02 | — | — | EP | disclosed |
| EP-0041935-B1 | N-(VINBLASTINOYL-23) DERIVATIVES OF AMINO ACIDS AND PEPTIDES AND THEIR PREPARATION | OMNICHEM Société anonyme (BE) | 1984-09-19 | — | — | EP | disclosed |
| EP-0041935-A1 | N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation | OMNICHEM Société anonyme (BE) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | IGLV6-57, GP6, VSIG8 | KDM4E 4430/4885MAPT 4417/4885MEN1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.